Phase II study of amonafide in patients with recurrent glioma

Ralph Levitt, Jan Craig Buckner, Terrence L. Cascino, Patrick A. Burch, Roscoe F. Morton, Mark W. Westberg, Richard M. Goldberg, James G. Gallagher, Judith R. O'Fallon, Bernd W. Scheithauer

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.

Original languageEnglish (US)
Pages (from-to)87-93
Number of pages7
JournalJournal of Neuro-Oncology
Volume23
Issue number1
DOIs
StatePublished - Feb 1995

Fingerprint

amonafide
Glioma
Imides
Phase II Clinical Trials
Astrocytoma
Vomiting
Cerebrospinal Fluid
Neoplasms
Animal Models
Population

Keywords

  • amonafide
  • astrocytoma
  • brain neoplasm
  • chemotherapy
  • glioma

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Levitt, R., Buckner, J. C., Cascino, T. L., Burch, P. A., Morton, R. F., Westberg, M. W., ... Scheithauer, B. W. (1995). Phase II study of amonafide in patients with recurrent glioma. Journal of Neuro-Oncology, 23(1), 87-93. https://doi.org/10.1007/BF01058464

Phase II study of amonafide in patients with recurrent glioma. / Levitt, Ralph; Buckner, Jan Craig; Cascino, Terrence L.; Burch, Patrick A.; Morton, Roscoe F.; Westberg, Mark W.; Goldberg, Richard M.; Gallagher, James G.; O'Fallon, Judith R.; Scheithauer, Bernd W.

In: Journal of Neuro-Oncology, Vol. 23, No. 1, 02.1995, p. 87-93.

Research output: Contribution to journalArticle

Levitt, R, Buckner, JC, Cascino, TL, Burch, PA, Morton, RF, Westberg, MW, Goldberg, RM, Gallagher, JG, O'Fallon, JR & Scheithauer, BW 1995, 'Phase II study of amonafide in patients with recurrent glioma', Journal of Neuro-Oncology, vol. 23, no. 1, pp. 87-93. https://doi.org/10.1007/BF01058464
Levitt R, Buckner JC, Cascino TL, Burch PA, Morton RF, Westberg MW et al. Phase II study of amonafide in patients with recurrent glioma. Journal of Neuro-Oncology. 1995 Feb;23(1):87-93. https://doi.org/10.1007/BF01058464
Levitt, Ralph ; Buckner, Jan Craig ; Cascino, Terrence L. ; Burch, Patrick A. ; Morton, Roscoe F. ; Westberg, Mark W. ; Goldberg, Richard M. ; Gallagher, James G. ; O'Fallon, Judith R. ; Scheithauer, Bernd W. / Phase II study of amonafide in patients with recurrent glioma. In: Journal of Neuro-Oncology. 1995 ; Vol. 23, No. 1. pp. 87-93.
@article{b7be7a545a2a4b0db8bd65e89c09fd6b,
title = "Phase II study of amonafide in patients with recurrent glioma",
abstract = "Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9{\%}) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.",
keywords = "amonafide, astrocytoma, brain neoplasm, chemotherapy, glioma",
author = "Ralph Levitt and Buckner, {Jan Craig} and Cascino, {Terrence L.} and Burch, {Patrick A.} and Morton, {Roscoe F.} and Westberg, {Mark W.} and Goldberg, {Richard M.} and Gallagher, {James G.} and O'Fallon, {Judith R.} and Scheithauer, {Bernd W.}",
year = "1995",
month = "2",
doi = "10.1007/BF01058464",
language = "English (US)",
volume = "23",
pages = "87--93",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II study of amonafide in patients with recurrent glioma

AU - Levitt, Ralph

AU - Buckner, Jan Craig

AU - Cascino, Terrence L.

AU - Burch, Patrick A.

AU - Morton, Roscoe F.

AU - Westberg, Mark W.

AU - Goldberg, Richard M.

AU - Gallagher, James G.

AU - O'Fallon, Judith R.

AU - Scheithauer, Bernd W.

PY - 1995/2

Y1 - 1995/2

N2 - Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.

AB - Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.

KW - amonafide

KW - astrocytoma

KW - brain neoplasm

KW - chemotherapy

KW - glioma

UR - http://www.scopus.com/inward/record.url?scp=0028947130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028947130&partnerID=8YFLogxK

U2 - 10.1007/BF01058464

DO - 10.1007/BF01058464

M3 - Article

VL - 23

SP - 87

EP - 93

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -